信函:阐明地中海饮食和限时喂养在MASLD管理中的协同作用机制-作者回复

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Sofia Tsitsou, Magdalini Adamantou, Triada Bali, Aristi Saridaki, Kalliopi-Anna Poulia, Dimitrios S. Karagiannakis, Emilia Papakonstantinou, Evangelos Cholongitas
{"title":"信函:阐明地中海饮食和限时喂养在MASLD管理中的协同作用机制-作者回复","authors":"Sofia Tsitsou,&nbsp;Magdalini Adamantou,&nbsp;Triada Bali,&nbsp;Aristi Saridaki,&nbsp;Kalliopi-Anna Poulia,&nbsp;Dimitrios S. Karagiannakis,&nbsp;Emilia Papakonstantinou,&nbsp;Evangelos Cholongitas","doi":"10.1111/apt.70178","DOIUrl":null,"url":null,"abstract":"<p>We sincerely thank Drs. Zhu and Zhou [<span>1</span>] for their thoughtful comments on our recent randomised study examining the effects of a 12-week Mediterranean-type time-restricted feeding (TRF) protocol in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) [<span>2</span>].</p><p>Our study is distinguished by the use of a hypocaloric Mediterranean diet as the control group, which has emerged as the gold standard for MASLD dietary management. This aligns with current recommendations emphasising lifestyle changes and a target weight loss of over 5% of initial body weight as primary treatment goals [<span>3, 4</span>]. Previous studies have shown that ad libitum TRF can lead to modest weight loss (1%–4%), while greater, clinically significant reductions typically require caloric restriction [<span>5</span>]. Therefore, combining TRF with a structured hypocaloric approach offers a promising avenue, as demonstrated by improvements in key metabolic parameters in our trial and others [<span>2, 6</span>].</p><p>We appreciate the pertinent questions raised regarding the underlying mechanisms and impact in specific sub-groups of such dietary interventions [<span>1</span>]. As pointed out in our original article [<span>2</span>], further research is needed to explore these complex interactions. Although a single clinical trial cannot address all knowledge gaps, we believe that our study lays the groundwork for future investigations in this scientific area. Ongoing planned analyses from our clinical trial may give insight into the field of circadian rhythms.</p><p>The authors' declarations of personal and financial interests are unchanged from those in the original article [<span>2</span>].</p><p><b>Sofia Tsitsou:</b> writing – original draft, investigation, methodology, data curation. <b>Magdalini Adamantou:</b> writing – original draft, data curation, investigation. <b>Triada Bali:</b> investigation, data curation. <b>Aristi Saridaki:</b> data curation, investigation. <b>Kalliopi-Anna Poulia:</b> methodology. <b>Dimitrios S. Karagiannakis:</b> methodology. <b>Emilia Papakonstantinou:</b> writing – review and editing, methodology. <b>Evangelos Cholongitas:</b> conceptualization, investigation, methodology, writing – review and editing, project administration, supervision, visualization, writing – original draft.</p><p>This article is linked to Tsitsou et al. paper. To view this article, visit, https://doi.org/10.1111/apt.70044 and https://doi.org/10.1111/apt.70154.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"61 12","pages":"1983-1984"},"PeriodicalIF":6.6000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70178","citationCount":"0","resultStr":"{\"title\":\"Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time-Restricted Feeding in MASLD Management—Authors' Reply\",\"authors\":\"Sofia Tsitsou,&nbsp;Magdalini Adamantou,&nbsp;Triada Bali,&nbsp;Aristi Saridaki,&nbsp;Kalliopi-Anna Poulia,&nbsp;Dimitrios S. Karagiannakis,&nbsp;Emilia Papakonstantinou,&nbsp;Evangelos Cholongitas\",\"doi\":\"10.1111/apt.70178\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>We sincerely thank Drs. Zhu and Zhou [<span>1</span>] for their thoughtful comments on our recent randomised study examining the effects of a 12-week Mediterranean-type time-restricted feeding (TRF) protocol in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) [<span>2</span>].</p><p>Our study is distinguished by the use of a hypocaloric Mediterranean diet as the control group, which has emerged as the gold standard for MASLD dietary management. This aligns with current recommendations emphasising lifestyle changes and a target weight loss of over 5% of initial body weight as primary treatment goals [<span>3, 4</span>]. Previous studies have shown that ad libitum TRF can lead to modest weight loss (1%–4%), while greater, clinically significant reductions typically require caloric restriction [<span>5</span>]. Therefore, combining TRF with a structured hypocaloric approach offers a promising avenue, as demonstrated by improvements in key metabolic parameters in our trial and others [<span>2, 6</span>].</p><p>We appreciate the pertinent questions raised regarding the underlying mechanisms and impact in specific sub-groups of such dietary interventions [<span>1</span>]. As pointed out in our original article [<span>2</span>], further research is needed to explore these complex interactions. Although a single clinical trial cannot address all knowledge gaps, we believe that our study lays the groundwork for future investigations in this scientific area. Ongoing planned analyses from our clinical trial may give insight into the field of circadian rhythms.</p><p>The authors' declarations of personal and financial interests are unchanged from those in the original article [<span>2</span>].</p><p><b>Sofia Tsitsou:</b> writing – original draft, investigation, methodology, data curation. <b>Magdalini Adamantou:</b> writing – original draft, data curation, investigation. <b>Triada Bali:</b> investigation, data curation. <b>Aristi Saridaki:</b> data curation, investigation. <b>Kalliopi-Anna Poulia:</b> methodology. <b>Dimitrios S. Karagiannakis:</b> methodology. <b>Emilia Papakonstantinou:</b> writing – review and editing, methodology. <b>Evangelos Cholongitas:</b> conceptualization, investigation, methodology, writing – review and editing, project administration, supervision, visualization, writing – original draft.</p><p>This article is linked to Tsitsou et al. paper. To view this article, visit, https://doi.org/10.1111/apt.70044 and https://doi.org/10.1111/apt.70154.</p>\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":\"61 12\",\"pages\":\"1983-1984\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2025-04-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.70178\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/apt.70178\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.70178","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

我们衷心感谢dr。Zhu和Zhou[1]对我们最近的一项随机研究进行了深思熟虑的评论,该研究考察了12周地中海型限时喂养(TRF)方案对代谢功能障碍相关脂肪变性肝病(MASLD)患者的影响。我们的研究的特点是使用低热量的地中海饮食作为对照组,这已经成为MASLD饮食管理的黄金标准。这与目前的建议一致,强调生活方式的改变和将体重减轻超过初始体重的5%作为主要治疗目标[3,4]。先前的研究表明,随意的TRF可以导致适度的体重减轻(1%-4%),而更大的,临床上显着的减少通常需要热量限制。因此,将TRF与结构化低热量方法相结合提供了一条很有前途的途径,正如我们的试验和其他试验中关键代谢参数的改善所证明的那样[2,6]。我们赞赏对此类饮食干预的潜在机制和对特定亚组的影响提出的相关问题[10]。正如我们在原始文章[2]中指出的那样,需要进一步的研究来探索这些复杂的相互作用。虽然单一的临床试验不能解决所有的知识差距,但我们相信我们的研究为未来在这一科学领域的研究奠定了基础。我们的临床试验正在进行的计划分析可能会对昼夜节律领域有深入的了解。作者的个人和经济利益声明与原文b[2]没有变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time-Restricted Feeding in MASLD Management—Authors' Reply

We sincerely thank Drs. Zhu and Zhou [1] for their thoughtful comments on our recent randomised study examining the effects of a 12-week Mediterranean-type time-restricted feeding (TRF) protocol in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) [2].

Our study is distinguished by the use of a hypocaloric Mediterranean diet as the control group, which has emerged as the gold standard for MASLD dietary management. This aligns with current recommendations emphasising lifestyle changes and a target weight loss of over 5% of initial body weight as primary treatment goals [3, 4]. Previous studies have shown that ad libitum TRF can lead to modest weight loss (1%–4%), while greater, clinically significant reductions typically require caloric restriction [5]. Therefore, combining TRF with a structured hypocaloric approach offers a promising avenue, as demonstrated by improvements in key metabolic parameters in our trial and others [2, 6].

We appreciate the pertinent questions raised regarding the underlying mechanisms and impact in specific sub-groups of such dietary interventions [1]. As pointed out in our original article [2], further research is needed to explore these complex interactions. Although a single clinical trial cannot address all knowledge gaps, we believe that our study lays the groundwork for future investigations in this scientific area. Ongoing planned analyses from our clinical trial may give insight into the field of circadian rhythms.

The authors' declarations of personal and financial interests are unchanged from those in the original article [2].

Sofia Tsitsou: writing – original draft, investigation, methodology, data curation. Magdalini Adamantou: writing – original draft, data curation, investigation. Triada Bali: investigation, data curation. Aristi Saridaki: data curation, investigation. Kalliopi-Anna Poulia: methodology. Dimitrios S. Karagiannakis: methodology. Emilia Papakonstantinou: writing – review and editing, methodology. Evangelos Cholongitas: conceptualization, investigation, methodology, writing – review and editing, project administration, supervision, visualization, writing – original draft.

This article is linked to Tsitsou et al. paper. To view this article, visit, https://doi.org/10.1111/apt.70044 and https://doi.org/10.1111/apt.70154.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信